文献速递乳腺外科围术期管理与 ERAS

靶向HER-2治疗与乳房重建结局的关联:倾向性评分匹配分析

Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
PubMed 文献 · J Am Coll Surg · 2017-10-03

本研究回顾性纳入2006至2016年在杜克大学医学中心接受化疗和乳房切除后重建的481例女性,按1:1倾向性评分匹配为107对,比较术前6周内接受靶向HER-2治疗与否对重建并发症的影响。结果显示,曲妥珠单抗联合帕妥珠单抗与需手术干预的伤口裂开风险独立相关(OR 65.29;95%CI 1.63至2611.50;p=0.03),而单药曲妥珠单抗与重建并发症无显著关联。结论提示曲妥珠单抗治疗无需延迟乳房重建,帕妥珠单抗的影响需进一步研究。

要点

  • 曲妥珠单抗单药与乳房重建并发症无显著关联。
  • 曲妥珠单抗联合帕妥珠单抗增加需手术干预的伤口裂开风险。
  • 曲妥珠单抗治疗不需延迟乳房重建。

核心结论

  • 曲妥珠单抗治疗与乳房重建手术并发症无显著关联,乳房重建无需因曲妥珠单抗给药而延迟。
  • 曲妥珠单抗联合帕妥珠单抗与需手术干预的伤口裂开风险独立相关,帕妥珠单抗对手术结局的影响需未来研究评估。

研究设计与样本

  • 回顾性识别2006至2016年在杜克大学医学中心接受化疗和乳房切除后重建的女性。
  • 将乳房重建前6周内接受曲妥珠单抗和/或帕妥珠单抗靶向HER-2治疗的患者,按年龄、肥胖、糖尿病、吸烟、新辅助化疗、化疗方案和放疗等因素1:1倾向性评分匹配至未接受靶向HER-2治疗的患者。
  • 共识别481例女性,形成107对倾向性评分匹配。

主要发现

  • 与未接受靶向HER-2治疗的患者相比,乳房重建前接受曲妥珠单抗联合帕妥珠单抗治疗与需手术干预闭合的术后伤口裂开风险增加独立相关(OR 65.29;95%CI 1.63至2611.50;p=0.03)。
  • 与较小肿瘤(<2 cm)相比,较大肿瘤(2至5 cm)与术后伤口裂开风险降低显著相关(OR 0.41;95%CI 0.19至0.87;p=0.02)。
  • 单药曲妥珠单抗靶向HER-2治疗与重建并发症无显著关联。

临床怎么用

  • 曲妥珠单抗治疗期间无需延迟乳房重建。
  • 对接受曲妥珠单抗联合帕妥珠单抗治疗的患者,应关注伤口裂开风险并加强术后监测。

局限性

  • 回顾性研究设计。
  • 帕妥珠单抗对手术结局的影响需未来研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current treatment for HER-2+ breast cancer includes chemotherapy and targeted HER-2 therapy with trastuzumab and/or pertuzumab. Evidence is lacking on the safety of breast reconstructive operations in these patients. We hypothesized that targeted HER-2 therapy was not associated with post-mastectomy reconstructive outcomes. STUDY DESIGN: Women receiving chemotherapy and post-mastectomy reconstruction at Duke University Medical Center from 2006 to 2016 were retrospectively identified. Patients receiving targeted HER-2 therapy with trastuzumab and/or pertuzumab within 6 weeks before breast reconstruction were propensity score-matched 1:1 to patients who did not receive targeted HER-2 therapy, based on the following factors: age, obesity, diabetes, tobacco use, receipt of neoadjuvant chemotherapy, chemotherapy regimen, and radiation therapy. Primary study outcomes included the occurrence of hematoma, seroma, infection, wound breakdown, mastectomy skin flap necrosis, and postoperative flap thrombosis. RESULTS: A total of 481 women were identified, resulting in 107 propensity score-matched pairs. Administration of combined trastuzumab and pertuzumab therapy before breast reconstruction was independently associated with increased risk of postoperative wound breakdown requiring operative intervention for closure, compared with patients not undergoing targeted HER-2 therapy (odds ratio 65.29; 95% CI 1.63 to 2,611.50; p = 0.03). In addition, larger tumor size (2 to 5 cm) was significantly associated with a reduced risk of postoperative wound breakdown, compared with smaller tumors (<2 cm) (odds ratio 0.41; 95% CI 0.19 to 0.87; p = 0.02). Single-agent targeted HER-2 therapy with trastuzumab was not significantly associated with reconstructive complications. CONCLUSIONS: Our study suggests that trastuzumab therapy in conjunction with breast reconstructive operation is not associated with reconstructive complications, and breast reconstruction does not need to be delayed due to the administration of trastuzumab. Future studies are needed to evaluate the impact of pertuzumab on surgical outcomes.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Shammas RL, Cho EH, Glener AD, et al. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. J Am Coll Surg. 2017. PMID: 28985927. doi:10.1016/j.jamcollsurg.2017.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。